Olfactory domain family protein 3 promotes the proliferation of MYCN-amplified neuroblastoma cell lines in vitro

doi:10.16352/j.issn.1001-6325.2025.02.0168

Abstract

Abstract: Objective To explore the function of olfactomedin domain family protein 3 (OLFM3) in neuroblastoma (NB). Methods The relationship between the expression of OLFM3 mRNA and v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog(MYCN)amplification status and the prognosis of patients in NB clinical samples were clarified by using R2 Genomics Analysis and Visualization Platform. Depmap database was used to examine the expression level of OLFM3 in different tumors cell lines and to identify the correlation between OLFM3 expression and MYCN amplification status in various NB cell lines. RT-qPCR and Western blot were used to detect the knockdown level of OLFM3. Cell proliferation was monitored using crystal violet staining and real-time cellular analysis. The colony formation ability of NB cells was assessed using colony-forming unit assay. Results Analysis of R2 database revealed higher level of OLFM3 expression in MYCN-amplified NB clinical samples(P＜0.001). Patients with high OLFM3 expression showed a significantly lower overall survival probability compared to those with low OLFM3 expression(P＜0.05). Analysis with Depmap database revealed that the expression level of OLFM3 was higher in NB than that in other kind of tumor. The expression level of OLFM3 was significantly higher in the MYCN-amplified cell lines than in the MYCN-non-amplified cell lines(P＜0.01). In MYCN-amplified NB cells, knockdown of OLFM3 inhibited cells proliferation(P＜0.001) and colony formation(P＜0.001), but there was no noticeable changes observed in MYCN-non-amplified cells. Conclusions OLFM3 specifically promotes the proliferation of MYCN-amplified NB cells, but has a less effect on MYCN-non-amplified cells, indicating it is a potential biomarker for high-risk MYCN-amplified NB.

Key words: neuroblastoma, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog(MYCN)amplification, olfactomedin domain family protein 3, cell proliferation

CLC Number:

R739.43

ZHANG Yao, ZHANG Xuan, JIA Anna, ZHAN Shijia, GUO Jinxin, CHANG Yan, GUO Yongli. Olfactory domain family protein 3 promotes the proliferation of MYCN-amplified neuroblastoma cell lines in vitro[J]. Basic & Clinical Medicine, 2025, 45(2): 168-175.

References 15

[1]	Qiu B, Matthay K. Advancing therapy for neuroblastoma[J]. Nat Rev Clin Oncol, 2022, 19: 515-533.
[2]	Wolpaw AJ, Bayliss R, Büchel G, et al. Drugging the “undruggable” MYCN oncogenic transcription factor: overcoming previous obstacles to impact childhood cancers[J]. Cancer Res, 2021, 81: 1627-1632.
[3]	Tomarev SI, Nakaya N. Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology[J]. Mol Neurobiol, 2009, 40: 122-138.
[4]	Tang S, Wang T, Zhang X, et al. Olfactomedin-3 enhances seizure activity by interacting with AMPA receptors in epilepsy models[J]. Front Cell Dev Biol, 2020, 8: 722, doi:10.3389/fcell.2020.00722.
[5]	Keenan J, Joyce H, Aherne S, et al. Olfactomedin Ⅲ expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line[J]. Exp Cell Res, 2012, 318: 593-602.
[6]	贾安娜,战世佳,张璇等. C12ORF66对MYCN扩增的高危神经母细胞瘤细胞的活性调控[J]. 基础医学与临床, 2024, 44:288-294.
[7]	Volegova MP, Brown LE, Banerjee U, et al. The MYCN 5' UTR as a therapeutic target in neuroblastoma[J]. Cell Rep, 2024, 43: 114134, doi:10.1016/j.celrep.2024.114134.
[8]	Hagemann S, Misiak D, Bell JL, et al. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression[J]. Mol Cancer, 2023, 22: 88, doi:10.1186/s12943-023-01792-0.
[9]	Dong Z, Yeo KS, Lopez G, et al. GAS7 Deficiency promotes metastasis in MYCN-driven neuroblastoma[J]. Cancer Res, 2021, 81: 2995-3007.
[10]	Zhou X, Wang X, Li N, et al. Therapy resistance in neuroblastoma: mechanisms and reversal strategies[J]. Front Pharmacol, 2023, 14: 1114295, doi:10.3389/fphar.2023.1114295.
[11]	Deng Z, Richardson DR, Insel P. The Myc family and the metastasis suppressor NDRG1: targeting key molecular interactions with innovative therapeutics[J]. Pharmacol Rev, 2023, 75: 1007-1035.
[12]	Lan MS, Chen C. Small molecules targeting INSM1 for the treatment of high-risk neuroblastoma[J]. Biology, 2023, 12: 1134, doi:10.3390/biology12081134.
[13]	Zafar A, Wang W, Liu G, et al. Targeting the p53-MDM2 pathway for neuroblastoma therapy: rays of hope[J]. Cancer Lett, 2021, 496: 16-29.
[14]	Li Z, Yang C, Li X, et al. The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells[J]. J Cancer, 2020, 11: 3274-3287.
[15]	Pham DC, Chang YC, Lin SR, et al. FAK and S6K1 inhibitor, Neferine, dually induces autophagy and apoptosis in human neuroblastoma cells[J]. Molecules, 2018, 23: 3110, doi:10.3390/molecules23123110.